Literature DB >> 7688505

A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects.

H X Lin1, C Gontier, M F Saron, P Perrin.   

Abstract

The activity of an immunostimulatory complex (PICKCa) which is widely used against several human diseases in China was tested in experimental rabies prophylaxis. PICKCa protected mice against peripheral infection with both fixed and wild rabies strains. It also enhanced the protective activity of an experimental rabies vaccine injected either before or after rabies infection. PICKCa enhanced both non-specific immune responses and specific immunity including antibody production and cell mediated immunity as assessed by interleukin-2 production.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7688505     DOI： 10.1007/bf01378634

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  25 in total

1.  Vaccines: recent trends and progress.

Authors:  A C Allison; G Gregoriadis
Journal:  Immunol Today       Date:  1990-12

2.  Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence.

Authors:  I MACPHERSON; M STOKER
Journal:  Virology       Date:  1962-02       Impact factor: 3.616

3.  Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment.

Authors:  I Vodopija; P Sureau; S Smerdel; M Lafon; Z Baklaić; M Ljubicić; M Svjetlicić
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

4.  A rapid reproducible test for determining rabies neutralizing antibody.

Authors:  J S Smith; P A Yager; G M Baer
Journal:  Bull World Health Organ       Date:  1973-05       Impact factor: 9.408

5.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

6.  Interleukin 2 increases protection against experimental rabies.

Authors:  P Perrin; M L Joffret; C Leclerc; D Oth; P Sureau; L Thibodeau
Journal:  Immunobiology       Date:  1988-05       Impact factor: 3.144

7.  Appraisal of rabies vaccine potency by determination of in vitro, specific interleukin-2 production.

Authors:  M L Joffret; C Zanetti; S Morgeaux; C Leclerc; P Sureau; P Perrin
Journal:  Biologicals       Date:  1991-04       Impact factor: 1.856

Review 8.  Rabies in China: recommendations for control.

Authors:  A Kureishi; L Z Xu; H Wu; H G Stiver
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

9.  Inhibition of immune responses against rabies virus by monoclonal antibodies directed against rabies virus antigens.

Authors:  C L Schumacher; H C Ertl; H Koprowski; B Dietzschold
Journal:  Vaccine       Date:  1992       Impact factor: 3.641
View more
  3 in total

Review 1.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05

2.  PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.

Authors:  Wei-wei Gai; Yan Zhang; Di-han Zhou; Yao-qing Chen; Jing-yi Yang; Hui-min Yan
Journal:  Virol Sin       Date:  2011-04-07       Impact factor: 4.327

3.  Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19.

Authors:  Jiao Tong; Chenxi Zhu; Hanyu Lai; Chunchao Feng; Dapeng Zhou
Journal:  Vaccines (Basel)       Date:  2021-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.